Abstract
Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Current Vascular Pharmacology
Title: New Anticoagulants for Prevention and Treatment of Venous Thromboembolism
Volume: 8 Issue: 3
Author(s): Lara N. Roberts and Roopen Arya
Affiliation:
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Abstract: Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Export Options
About this article
Cite this article as:
N. Roberts Lara and Arya Roopen, New Anticoagulants for Prevention and Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112232
DOI https://dx.doi.org/10.2174/157016110791112232 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry: An Attractive and Prospective Method for Quantitative Bioanalysis in Drug Metabolism
Current Drug Metabolism Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Placental Cytokines in the Pathogenesis of Preeclampsia and Hellp Syndrome
Current Women`s Health Reviews Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology In Vivo Gamma Scintigraphic Evaluation and Determination of a Gastro-Resistant Etodolac Tablet in Humans
Combinatorial Chemistry & High Throughput Screening Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) The Right Ventricle: Biologic Insights and Response to Disease
Current Cardiology Reviews Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials